| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6193697 | Practical Radiation Oncology | 2012 | 6 Pages |
Abstract
There is a higher incidence of HO among the morbidly obese patients despite RT ± indomethacin. RT doses for HO prophylaxis in morbidly obese patients need to be reassessed; also, understanding the signaling pathways in target tissues in obese patients at which adipokines control metabolism may reveal novel therapies. Higher radiation doses ± indomethacin may need to be considered and optimally evaluated in the context of a prospective, randomized clinical trial.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Waleed Fouad MD, MSc, PhD, Satya MD, PhD, Rania A. MPH, Zhen MS, Majid A. MD, Matthew MD, Michael C. MD, George MD, Srinivasan MD,